EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor‐Expressed SPPL3 Supports Innate Antitumor Immune Responses

Tamara Verkerk, Antonius A de Waard, Sofie J I Koomen, Jasper Sanders, Tineke Jorritsma, Anouk T Pappot, Nordin D Zandhuis, Tao Zhang, Manfred Wuhrer, Arie J Hoogendijk, Floris P J van Alphen, Maartje van den Biggelaar und 4 weitere

European Journal of Immunology · 2025

DOI: 10.1002/eji.202451129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Tamara Verkerk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Immunity, Innate, Killer Cells, Natural, Neutrophils, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Research Council/Exacte en Natuurwetenschappen, KWF Alpe d'HuZes, Landsteiner Foundation for Blood Transfusion Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of an effective antitumor response relies on the synergistic actions of various immune cells that recognize tumor cells via distinct receptors. Tumors, however, often manipulate receptor–ligand interactions to evade recognition by the immune system. Recently, we highlighted the role of neolacto‐series glycosphingolipids (nsGSLs), produced by the enzyme β1,3‐ N ‐acetylglucosaminyltransferase 5 (B3GNT5), in tumor immune escape. We previously demonstrated that loss of signal peptide peptidase like 3 (SPPL3), an inhibitor of B3GNT5, results in elevated levels of nsGSLs and impairs CD8 T cell activation. The impact of loss of SPPL3 and an elevated nsGSL profile in tumor cells on innate immune recognition remains to be elucidated. This study investigates the antitumor efficacy of neutrophils, NK cells, and γδ T cells on tumor cells lacking SPPL3. Our findings demonstrate that SPPL3‐deficient target cells are less susceptible to trogocytosis by neutrophils and killing by NK cells and γδ T cells. Mechanistically, SPPL3 influences trogocytosis and γδ T cell‐instigated killing through modulation of nsGSL expression, whereas SPPL3‐mediated reduced killing by NK cells is nsGSL‐independent. The nsGSL‐dependent SPPL3 sensitivity depends on the proximity of surface receptor domains to the cell membrane and the affinity of receptor–ligand interactions as shown with various sets of defined antibodies. Thus, SPPL3 expression by tumor cells alters crosstalk with immune cells through the receptor–ligand interactome thereby driving escape not only from adaptive but also from innate immunity. These data underline the importance of investigating a potential synergism of GSL synthesis inhibitors with current immune cell‐activating immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunity, InnateKiller Cells, NaturalNeutrophilsNeoplasmsAnimalsMiceHumansCell Line, TumorTrogocytosisTumor EscapeMice, Inbred C57BLMice, KnockoutLymphocyte Activation

Autor:innen und Institutionen

  • Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
  • Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
  • Center for Proteomics and Metabolomics, LUMC, Leiden, The Netherlands.
  • Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands.
  • Institute for Hygiene and Applied Immunology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Wien, Austria.

ORCID-Profile: Klaas P J M van Gisbergen

Förderung

  • Dutch Research Council/Exacte en Natuurwetenschappen
  • KWF Alpe d'HuZes
  • Landsteiner Foundation for Blood Transfusion Research

Zitieren

APA

Verkerk, T., de Waard, A. A., Koomen, S. J. I., Sanders, J., Jorritsma, T., Pappot, A. T., Zandhuis, N. D., Zhang, T., Wuhrer, M., Hoogendijk, A. J., van Alphen, F. P. J., van den Biggelaar, M., Stockinger, H. S. J., van Gisbergen, K. P. J. M., Spaapen, R. M., & van Ham, S. M. (2025). Tumor‐Expressed SPPL3 Supports Innate Antitumor Immune Responses. European Journal of Immunology. https://doi.org/10.1002/eji.202451129

Vancouver

Verkerk T, de Waard AA, Koomen SJI, Sanders J, Jorritsma T, Pappot AT, et al. Tumor‐Expressed SPPL3 Supports Innate Antitumor Immune Responses. European Journal of Immunology. 2025. doi:10.1002/eji.202451129

BibTeX
@article{Verkerk2025,
  author = {Verkerk, Tamara and de Waard, Antonius A and Koomen, Sofie J I and Sanders, Jasper and Jorritsma, Tineke and Pappot, Anouk T and Zandhuis, Nordin D and Zhang, Tao and Wuhrer, Manfred and Hoogendijk, Arie J and van Alphen, Floris P J and van den Biggelaar, Maartje and Stockinger, Hannes S J and van Gisbergen, Klaas P J M and Spaapen, Robbert M and van Ham, S Marieke},
  title = {Tumor‐Expressed SPPL3 Supports Innate Antitumor Immune Responses},
  journal = {European Journal of Immunology},
  year = {2025},
  doi = {10.1002/eji.202451129}
}
Kostenlos starten →